PUBLISHER: DelveInsight | PRODUCT CODE: 1226625
PUBLISHER: DelveInsight | PRODUCT CODE: 1226625
"KISQALI Drug Insight and Market Forecast - 2032" report provides comprehensive insights about KISQALI for ER +ve HER2-ve Breast Cancer in the United States. A detailed picture of the KISQALI for ER+ve HER2-ve Breast Cancer in the United States for the study period 2019-2032 is provided in this report along with a detailed description of the KISQALI for ER+ve HER2-ve Breast Cancer. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the KISQALI market forecast, analysis for ER+ve HER2-ve Breast Cancer in the United States, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in ER+ve HER2-ve Breast Cancer.
KISQALI (Ribociclib; LEE011) is a kinase inhibitor indicated for the treatment of adult patients with HR+, HER2- advanced or metastatic cancer in combination with:
The recommended dose of KISQALI is 600 mg (three 200 mg film-coated tablets) taken orally, once daily for 21 consecutive days, followed by 7 days off treatment resulting in a complete cycle of 28 days. KISQALI can be taken with or without food. When given with KISQALI, the recommended dose of fulvestrant is 500 mg administered on Days 1, 15, 29, and once monthly thereafter.
KISQALI is a cyclin-dependent kinase (CDK4/6 inhibitor). These kinases are activated upon binding to D-cyclins and play a vital role in signaling pathways that lead to cell cycle progression and cellular proliferation. The cyclin D-CDK4/6 complex regulates cell cycle progression through phosphorylation of the retinoblastoma protein (pRb).
A combination of ribociclib and antiestrogen (e.g., letrozole) resulted in increased tumor growth inhibition compared to each drug alone. Additionally, the combination of ribociclib and fulvestrant resulted in tumor growth inhibition in ER+ breast cancer.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
KISQALI Analytical Perspective by DelveInsight
This report provides a detailed market assessment of KISQALI in ER+ve HER2-ve Breast Cancer in the United States. This segment of the report provides forecasted sales data from 2023 to 2032.
The report provides the clinical trials information of KISQALI in ER+ve HER2-ve Breast Cancer covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions